Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

King, J. R.; Acosta, E. P.; Yogev, R.; Wiznia, A.; Kraimer, J.; Graham, B.; Carey, V.; Britto, P.; Jean-Philippe, P.; Moye, J.; Watson, D.

Pediatr Infect Dis J. 2008 Dec 25; 28(2):159-61

Abstract

The pharmacokinetics of lopinavir/ritonavir (LPV/RTV) 300 mg/m twice daily and efavirenz (EFV) 350 mg/m once daily were evaluated in HIV-infected children. The minimum concentrations for LPV contained values above the target range, and the estimated minimum concentrations for EFV contained values below the range. Our data support the current LPV/RTV dose, but EFV 350 mg/m may not be sufficient.

Read More on PubMed